GeneTex
United States (US)

AIF peptide

img12245_18121411_744.jpg

Cat No. GTX27871

Application Blocking, IHC
Species Human
APPLICATION

Application Note

The peptide is used for blocking the antibody activity of AIF. It usuallyblocks the antibody activity completely in Western blot by incubating the peptide with equalvolume of antibody for 30 min at 37ºC
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Background

Apoptosis is characterized by several morphological nuclear changes including chromatin condensation and nuclear fragmentation. These changes are triggered by the activation of members of caspase family, caspase activated DNase, and several novel proteins. A novel gene, the product of which causes chromatin condensation and DNA fragmentation, was recently identified, cloned, and designated apoptosis inducing factor (AIF). Like the critical molecules, cytochrome c and caspase-9, in apoptosis, AIF localizes in mitochondria. AIF translocates to the nucleus when apoptosis is induced and induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. AIF induces chromatin condensation and large scale DNA fragmentation, which are the hallmarks of apoptosis, of the isolated nucleus and the nucleus in live cells by microinjection and apoptosis stimuli. AIF is highly conserved between human and mouse and widely expressed.

Research Area

DATA IMAGES
img12245_18121411_744.jpg

GTX27871 IHC Image


Package List Price ($)
$ 179